article Open AccessTop 10% cited

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

BMC Cancer · 2009 · Vol. 9(1) · pp. 1–1

Dara O. Kavanagh✉(Mayo General Hospital)Gillian Chambers(Mayo General Hospital)Liam O' Grady(Mayo General Hospital)Kevin M. Barry(Mayo General Hospital)R. Waldron(Mayo General Hospital)Fadel Bennani(Mayo General Hospital)Paul W. Eustace(Mayo General Hospital)I Tobbia(Mayo General Hospital)

View via DOI Full-text PDF

Abstract

HER-2 protein is over expressed in 11% of colorectal cancer patients. The gene encoding HER-2 is amplified in 3% of cases. Overexpression of HER-2 is not a predictor of outcome. However, patients who over express HER-2 may respond to Herceptin therapy.

HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies Gastric Cancer Management and OutcomesSurgical oncologyColorectal cancerMedicineOncologyInternal medicineCancerGeneral surgery

MeSH terms

AdultAgedAged, 80 and overFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm StagingPrognosisColorectal NeoplasmsCohort StudiesGene Expression Regulation, NeoplasticReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases